PhaseRx (PhaseRx) Inventory-to-Revenue : 0.00 (As of Sep. 2017)

View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. PhaseRx's Average Total Inventories for the quarter that ended in Sep. 2017 was $0.00 Mil. PhaseRx's Revenue for the three months ended in Sep. 2017 was $0.00 Mil.

PhaseRx's Inventory-to-Revenue for the quarter that ended in Sep. 2017 stayed the same from Jun. 2017 (0.00) to Jun. 2017 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

PhaseRx Inventory-to-Revenue Historical Data

The historical data trend for PhaseRx's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Inventory-to-Revenue Chart

PhaseRx Annual Data

Trend

Dec14

Dec15

Dec16

Inventory-to-Revenue

PhaseRx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Inventory-to-Revenue	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of PhaseRx's Inventory-to-Revenue

For the Biotechnology subindustry, PhaseRx's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseRx's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where PhaseRx's Inventory-to-Revenue falls into.

PhaseRx Inventory-to-Revenue Calculation

PhaseRx's Inventory-to-Revenue for the fiscal year that ended in Dec. 2016 is calculated as

	Inventory-to-Revenue (A: Dec. 2016 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2015 )	+	Total Inventories (A: Dec. 2016 ))	/	count )	/	Revenue (A: Dec. 2016 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

PhaseRx's Inventory-to-Revenue for the quarter that ended in Sep. 2017 is calculated as

	Inventory-to-Revenue (Q: Sep. 2017 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2017 )	+	Total Inventories (Q: Sep. 2017 ))	/	count )	/	Revenue (Q: Sep. 2017 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

PhaseRx (OTCPK:PZRXQ) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PhaseRx's Days Inventory for the three months ended in Sep. 2017 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2017 )	/	Cost of Goods Sold (Q: Sep. 2017 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

PhaseRx's Inventory Turnover for the quarter that ended in Sep. 2017 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2017 )	/	Average Total Inventories (Q: Sep. 2017 )
	=	0	/	0
	=

PhaseRx Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of PhaseRx's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseRx (PhaseRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119

Website

http://www.phaserx.com

PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.

Executives

Gordon Brandt	officer: Chief Medical Officer	410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr	director	300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm • 05-24-2016

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio • 10-13-2017